|Title:||Methods and compositions for inhibition of angiogenesis|
|Abstract:||The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.|
|Inventor(s):||D'Amato; Robert (Lancaster, PA)|
|Assignee:||Childrens Hospital Medical Center Corp. (Boston, MA)|
Patent Claim Types:|
see list of patent claims
|Country||Document Number||Publication Date||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|European Patent Office||0688211||May 21, 1997||SPC025/2008||Ireland||<disabled>|
|Netherlands||300358||Jun 02, 2009|
|Colombia||4230017||Oct 19, 1995|
|Portugal||688211||Nov 29, 2002|
|European Patent Office||0688211||Dec 27, 1995||91471||Luxembourg||<disabled>|
|This preview shows a limited data set|
Subscribe for full access
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.